Avancerad sökning
Visar resultat 1 - 5 av 25 avhandlingar som matchar ovanstående sökkriterier.
1. Cyclin A1 Expression and Regulation in Hematopoietic and Leukemic Cells
Sammanfattning : Increased expression of the cell cycle regulatory protein cyclin A1 has previously been detected in patients with acute myeloid leukemia (AML) and targeted overexpression of cyclin A1 in a transgenic mouse model initiated AML. The aim of this thesis was to further study the expression and regulation of cyclin A1 in hematopoietic cells. LÄS MER
2. Role of cyclin D1 as an estrogen receptor cofactor and the influence of hypoxia on estrogen receptor regulation, with focus on prognositic and treatment predictive features in breast cancer
Sammanfattning : Estrogen receptor (ER) status can define breast cancer patients who would benefit from adjuvant tamoxifen therapy. However, resistance to tamoxifen is often observed and possible mechanisms may be loss or reduction of ER, dysfunctional ER- signaling and ligand independent activation of the receptor. LÄS MER
3. Proliferation, Invasion and p16 Localisation in Malignancies
Sammanfattning : Uncontrolled proliferation and invasion are two characteristics in tumour development and progression. Previous studies have shown that invading tumour cells in colorectal cancer have low proliferation in parallel to upregulation of the tumour suppressor p16. LÄS MER
4. Predictive markers for tamoxifen response in primary breast cancer
Sammanfattning : It is well-known that a majority of breast cancers are hormone-dependent, making endocrine therapy an important adjuvant treatment after surgery. Susceptibility to endocrine treatment is determined by the presence of estrogen receptors (ER) and progesterone receptors (PR) in the tumors. LÄS MER
5. Cyclin E overexpression and associated events in human breast cancer
Sammanfattning : Unrestrained proliferation is a hallmark of cancer and genetic defects within G1/S-phase regulation and the pRb pathway occur frequently. Proliferation control can be circumvented either by excess cyclin D1 or cyclin E, alterations that can define two alternative tumour biologic pathways in breast cancer. LÄS MER